Manufacturers report positive results for lenvatinib in combination with pembrolizumab and/or everolimus in phase 3 KEYNOTE-581/CLEAR Trial

In the study (n=1050), these combination regimens improved progression-free survival (primary endpoint), overall survival and objective response rate vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma.

Biospace Inc.